Bottom line
What is TNRAX's expense ratio?
TNRAX's expense ratio is 0.9%, or about $90 a year on every $10,000 invested. That is more expensive than 54% of large growth funds we track (median 0.87%). This share class also charges a front-end sales load of up to 5.5%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Feb 24, 2026
TNRAX fee table
| Net expense ratio | 0.9% |
|---|---|
| Gross expense ratio | 1.04% |
| Management fee | 0.5% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.29% |
| Fee waiver / reimbursement | -0.14% |
| Max front-end sales load | 5.5% |
| Max deferred sales charge | 1% |
Source: Fund prospectus fee table, filed Feb 24, 2026
What TNRAX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| TNRAX | $637 | $850 | $1,080 | $1,739 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 0.9% expense ratio costs roughly $50,300 in lost growth, versus about $48,700 for the median large growth fund (0.87%).
Cheaper alternatives to TNRAX
These funds have a similar portfolio (by top-holdings overlap) and a lower expense ratio. Savings are per $10,000 invested.
*Difference in ending value of $10,000 after 20 years at a 6% gross annual return, net of each fund's expense ratio.